U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

After two days of making his case to Senate committees, Robert F. Kennedy Jr.’s bid to lead federal health agencies still ...

Pleas note: we will be discontinuing the Global Markets Report after 28 February. Australian shares are set to open lower, ...

The S&P 500 declined by 0.5% on Friday, Jan. 31, as investors digested the White House’s proposed tariffs on Canada, China, and Mexico.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in. The content of this article is provided for information ...

Our writer thinks these two speculative shares offer high long-term growth potential from where they currently sit in the stock market. When investing, your capital is at risk. The value of your ...

Stocks have support on better-than-expected stock earnings news. Apple is up more than +2% after forecasting a ...

Real-time index price for Dow Jones Transportations Average (DOWT), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...

BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...